Xbrane Biopharma AB (CHIX:XBRANS) Cyclically Adjusted Revenue per Share: kr26,522.41 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:XBRANS Xbrane Biopharma AB CHIX:XBRANS
71 GF Score
Price kr3,825.00
GF Value kr2,435.92
! 6 Warning Signs
View Full Analysis

What is Xbrane Biopharma AB Cyclically Adjusted Revenue per Share?

Xbrane Biopharma AB CHIX:XBRANS 71 Cyclically Adjusted Revenue per Share is kr26,522.41 as of Jun. 2026. GuruFocus rates CHIX:XBRANS with a GF Score™ of 71/100 and a GF Value™ of kr2,435.92. The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Xbrane Biopharma AB's adjusted revenue per share for the three months ended in Jun. 2026 was kr2.269. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is kr26,522.41 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Xbrane Biopharma AB's average Cyclically Adjusted Revenue Growth Rate was -0.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-31), Xbrane Biopharma AB's current stock price is kr3825.00. Xbrane Biopharma AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was kr26,522.41. Xbrane Biopharma AB's Cyclically Adjusted PS Ratio of today is 0.14.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Xbrane Biopharma AB was 0.49. The lowest was 0.08. And the median was 0.27.


Xbrane Biopharma AB  (CHIX:XBRANs) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Xbrane Biopharma AB's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=3825.00/26522.41
=0.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Xbrane Biopharma AB was 0.49. The lowest was 0.08. And the median was 0.27.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Xbrane Biopharma AB Cyclically Adjusted Revenue per Share Related Terms


Xbrane Biopharma AB Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Xbrane Biopharma AB's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xbrane Biopharma AB Cyclically Adjusted Revenue per Share Chart

Xbrane Biopharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 14,133.47 27,551.25

Xbrane Biopharma AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8,826.19 8,648.08 27,551.25 44,069.74 26,522.41

CHIX:XBRANS vs VRTX, REGN, MRNA: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Xbrane Biopharma AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xbrane Biopharma AB Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xbrane Biopharma AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Xbrane Biopharma AB's Cyclically Adjusted PS Ratio falls into.


CHIX:XBRANS
71GF Score
Xbrane Biopharma AB CHIX:XBRANS
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xbrane Biopharma AB Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Xbrane Biopharma AB's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=2.269/134.6100*134.6100
=2.269

Current CPI (Jun. 2026) = 134.6100.

Xbrane Biopharma AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.000 101.138 0.000
201612 0.000 102.022 0.000
201703 19.322 102.022 25.494
201706 11.882 102.752 15.566
201709 0.000 103.279 0.000
201712 23.218 103.793 30.112
201803 20.084 103.962 26.005
201806 10.300 104.875 13.220
201809 4.786 105.679 6.096
201812 206.718 105.912 262.731
201903 0.000 105.886 0.000
201906 0.000 106.742 0.000
201909 0.000 107.214 0.000
201912 0.550 107.766 0.687
202003 0.000 106.563 0.000
202006 0.000 107.498 0.000
202009 0.000 107.635 0.000
202012 4.805 108.296 5.973
202103 1.624 108.360 2.017
202106 1.624 108.928 2.007
202109 1.312 110.338 1.601
202112 1.739 112.486 2.081
202203 4.131 114.825 4.843
202206 10.633 118.384 12.090
202209 7.949 122.296 8.749
202212 9.141 126.365 9.737
202303 31.839 127.042 33.736
202306 25.640 129.407 26.671
202309 28.546 130.224 29.508
202312 31.812 131.912 32.463
202403 1.149 132.205 1.170
202406 4.250 132.716 4.311
202409 1.316 132.304 1.339
202412 0.043 132.987 0.044
202503 7.606 132.825 7.708
202506 0.026 133.699 0.026
202509 0.490 133.480 0.494
202512 0.020 133.390 0.020
202603 0.841 133.560 0.848
202606 2.269 134.610 2.269

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of kr26,522.41 mean?
Xbrane Biopharma AB (CHIX:XBRANS) has a Cyclically Adjusted Revenue per Share of kr26,522.41 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Xbrane Biopharma AB and its competitors.
Is Xbrane Biopharma AB's Cyclically Adjusted Revenue per Share too high?
Xbrane Biopharma AB's current Cyclically Adjusted Revenue per Share is kr26,522.41. Overall, Xbrane Biopharma AB has a GF Score™ of 71/100, reflecting its overall financial health beyond just this single metric.
How does Xbrane Biopharma AB's Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
Xbrane Biopharma AB's Cyclically Adjusted Revenue per Share of kr26,522.41 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Xbrane Biopharma AB and its competitors. Xbrane Biopharma AB's current Cyclically Adjusted Revenue per Share is kr26,522.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xbrane Biopharma AB stock overvalued right now?
Xbrane Biopharma AB (CHIX:XBRANS) has a current Cyclically Adjusted Revenue per Share of kr26,522.41. The stock's GF Value™ is kr2,435.92, compared to a current price of kr3,825.00 — trading 57% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is kr26,522.41. Xbrane Biopharma AB's overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Xbrane Biopharma AB (CHIX:XBRANS), the current Cyclically Adjusted Revenue per Share is kr26,522.41 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xbrane Biopharma AB (CHIX:XBRANS) Overvalued in 2026?

Based on GuruFocus' analysis, Xbrane Biopharma AB stock appears to be overvalued. The current stock price of kr3,825.00 is trading 57% above its estimated GF Value™ of kr2,435.92.

Key valuation signals for CHIX:XBRANS:

  • Cyclically Adjusted Revenue per Share: kr26,522.41
  • GF Value™: kr2,435.92 vs. price of kr3,825.00 (57% above fair value)
  • GF Score™: 71/100 with 6 warning signs

No single metric tells the full story. See the CHIX:XBRANS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Xbrane Biopharma AB Business Description

Other Exchanges XBRANE:Sweden7XB0:Germany
Address Scheeles vag 5, Solna, SWE, 171 65
Xbrane Biopharma AB is a biotechnology company that develops biosimilars. The company follows drugs on already approved biological drugs that can be introduced at a lower price after the patent expires on the original drug. The company has a patented protein production platform with greater productivity than standard systems for producing proteins in E.coli host cells. The company's product candidate is Ximluci, a ranibizumab biosimilar (original drug Lucentis) used in the treatment of various eye diseases, mainly the wet form of age-related macular degeneration. Other products in preclinical stage of the company includes Xdivane and Xdarzane.
71GF Score

Get the complete analysis for CHIX:XBRANS

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr3,825.00
Price
kr2,435.92
GF Value